Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer

The clinical efficacy of epidermal growth factor receptor (EGFR)–targeted therapy in EGFR-mutant non–small cell lung cancer is limited by the development of drug resistance. One mechanism of EGFR inhibitor resistance occurs through amplification of the human growth factor receptor (MET) proto-oncoge...

Descripción completa

Detalles Bibliográficos
Autores principales: Eser, Pınar Özden, Paranal, Raymond M., Son, Jieun, Ivanova, Elena, Kuang, Yanan, Haikala, Heidi M., To, Ciric, Okoro, Jeffrey J., Dholakia, Kshiti H., Choi, Jihyun, Eum, Yoonji, Ogino, Atsuko, Missios, Pavlos, Ercan, Dalia, Xu, Man, Poitras, Michael J., Wang, Stephen, Ngo, Kenneth, Dills, Michael, Yanagita, Masahiko, Lopez, Timothy, Lin, Mika, Tsai, Jeanelle, Floch, Nicolas, Chambers, Emily S., Heng, Jennifer, Anjum, Rana, Santucci, Alison D., Michael, Kesi, Schuller, Alwin G., Cross, Darren, Smith, Paul D., Oxnard, Geoffrey R., Barbie, David A., Sholl, Lynette M., Bahcall, Magda, Palakurthi, Sangeetha, Gokhale, Prafulla C., Paweletz, Cloud P., Daley, George Q., Jänne, Pasi A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627689/
https://www.ncbi.nlm.nih.gov/pubmed/34516823
http://dx.doi.org/10.1126/scitranslmed.abb3738

Ejemplares similares

Ejemplares similares